JP2007503384A - 肥満症の治療又は体重減量を容易にする若しくは促進するための医薬組成物 - Google Patents
肥満症の治療又は体重減量を容易にする若しくは促進するための医薬組成物 Download PDFInfo
- Publication number
- JP2007503384A JP2007503384A JP2006523699A JP2006523699A JP2007503384A JP 2007503384 A JP2007503384 A JP 2007503384A JP 2006523699 A JP2006523699 A JP 2006523699A JP 2006523699 A JP2006523699 A JP 2006523699A JP 2007503384 A JP2007503384 A JP 2007503384A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- triene
- diazocin
- methano
- pyrido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 39
- 235000020824 obesity Nutrition 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 230000004580 weight loss Effects 0.000 title claims description 17
- 230000001737 promoting effect Effects 0.000 title claims description 6
- 239000003446 ligand Substances 0.000 claims abstract description 29
- 229960002715 nicotine Drugs 0.000 claims abstract description 27
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 25
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000004031 partial agonist Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 18
- 206010033307 Overweight Diseases 0.000 claims abstract description 13
- 206010020710 Hyperphagia Diseases 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 10
- 235000020830 overeating Nutrition 0.000 claims abstract description 10
- -1 1-aminomethyl-cyclohexylmethyl Chemical group 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- BIGWXAGEQONZGD-UHFFFAOYSA-N 2h-oxadiazol-5-one Chemical compound O=C1C=NNO1 BIGWXAGEQONZGD-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 9
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 8
- DWDCLEHDNICBMI-UHFFFAOYSA-N 3-bromocytisine Chemical compound C1C2CNCC1CN1C2=CC=C(Br)C1=O DWDCLEHDNICBMI-UHFFFAOYSA-N 0.000 claims description 8
- JTVKNZNCCOMFMG-UHFFFAOYSA-N C1C2CNCC1CC1=C2C=CC=C1C(F)(F)F Chemical compound C1C2CNCC1CC1=C2C=CC=C1C(F)(F)F JTVKNZNCCOMFMG-UHFFFAOYSA-N 0.000 claims description 8
- HYHCJHBDDKMCTD-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(F)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(F)C1=O HYHCJHBDDKMCTD-UHFFFAOYSA-N 0.000 claims description 8
- GQVTUDRXPMPVRX-UHFFFAOYSA-N chembl62858 Chemical compound C1C2CNCC1CN1C2=CC=C(I)C1=O GQVTUDRXPMPVRX-UHFFFAOYSA-N 0.000 claims description 8
- NBGMTBMAENFSAW-UHFFFAOYSA-N chembl64496 Chemical compound C1C2CNCC1CN1C2=CC=C(Cl)C1=O NBGMTBMAENFSAW-UHFFFAOYSA-N 0.000 claims description 8
- HYDLTSOVXCUHPA-UHFFFAOYSA-N ctk0j4563 Chemical compound C1NCC2CC3=C(F)C(F)=CC=C3C1C2 HYDLTSOVXCUHPA-UHFFFAOYSA-N 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 8
- WCHRGFOUQHTVRJ-UHFFFAOYSA-N 2-[2-(2,4-dichlorophenoxy)ethylamino]acetic acid Chemical compound OC(=O)CNCCOC1=CC=C(Cl)C=C1Cl WCHRGFOUQHTVRJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 229960002870 gabapentin Drugs 0.000 claims description 5
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 5
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 4
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- VHMDFCVLQUZHMQ-UHFFFAOYSA-N 9-vinyl-1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2-a][1,5]diazocin-8-one Chemical compound C1C2CNCC1CN1C2=CC=C(C=C)C1=O VHMDFCVLQUZHMQ-UHFFFAOYSA-N 0.000 claims description 4
- ZUXXFRXUPFGGPW-UHFFFAOYSA-N C12=CC=C(Br)C(=O)N2CC2CN(C)CC1C2 Chemical compound C12=CC=C(Br)C(=O)N2CC2CN(C)CC1C2 ZUXXFRXUPFGGPW-UHFFFAOYSA-N 0.000 claims description 4
- MYEABNSFVNHLCV-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(C)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(C)C1=O MYEABNSFVNHLCV-UHFFFAOYSA-N 0.000 claims description 4
- HRVMVUUOSIHXEI-UHFFFAOYSA-N C1C2CNCC1CN1C2=CC=C(CC)C1=O Chemical compound C1C2CNCC1CN1C2=CC=C(CC)C1=O HRVMVUUOSIHXEI-UHFFFAOYSA-N 0.000 claims description 4
- VIPDMOOFKWHQRH-UHFFFAOYSA-N C1N2C(=O)C(Br)=CC=C2C(C2)CC1CN2CC1=CC=CC=C1 Chemical compound C1N2C(=O)C(Br)=CC=C2C(C2)CC1CN2CC1=CC=CC=C1 VIPDMOOFKWHQRH-UHFFFAOYSA-N 0.000 claims description 4
- AMUBSCCNOIMNNS-UHFFFAOYSA-N C1N2C(=O)C(Cl)=CC=C2C(C2)CC1CN2CC1=CC=CC=C1 Chemical compound C1N2C(=O)C(Cl)=CC=C2C(C2)CC1CN2CC1=CC=CC=C1 AMUBSCCNOIMNNS-UHFFFAOYSA-N 0.000 claims description 4
- MGQATKFFMYTJKY-UHFFFAOYSA-N C=1C=C2C(C3)CNCC3CN2C(=O)C=1C1=CC=CC=C1 Chemical compound C=1C=C2C(C3)CNCC3CN2C(=O)C=1C1=CC=CC=C1 MGQATKFFMYTJKY-UHFFFAOYSA-N 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- IVYDEZGCXPEAHO-HTQZYQBOSA-N (2r,4r)-2-(aminomethyl)-4-methylheptanoic acid Chemical compound CCC[C@@H](C)C[C@H](CN)C(O)=O IVYDEZGCXPEAHO-HTQZYQBOSA-N 0.000 claims description 3
- IVYDEZGCXPEAHO-JGVFFNPUSA-N (2r,4s)-2-(aminomethyl)-4-methylheptanoic acid Chemical compound CCC[C@H](C)C[C@H](CN)C(O)=O IVYDEZGCXPEAHO-JGVFFNPUSA-N 0.000 claims description 3
- GUEQOLSQPOTTME-RQJHMYQMSA-N (3s,5r)-3-amino-5-methylheptanoic acid Chemical compound CC[C@@H](C)C[C@H](N)CC(O)=O GUEQOLSQPOTTME-RQJHMYQMSA-N 0.000 claims description 3
- XKWDZEJCUWTBOM-BDAKNGLRSA-N (3s,5r)-3-amino-5-methylnonanoic acid Chemical compound CCCC[C@@H](C)C[C@H](N)CC(O)=O XKWDZEJCUWTBOM-BDAKNGLRSA-N 0.000 claims description 3
- VNEAZJRSFULCJJ-YPMHNXCESA-N (3s,5r)-3-amino-7-cyclohexyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](N)C[C@H](C)CCC1CCCCC1 VNEAZJRSFULCJJ-YPMHNXCESA-N 0.000 claims description 3
- HDLUMIBBUPOCSA-PWSUYJOCSA-N (3s,5r)-3-amino-7-cyclopentyl-5-methylheptanoic acid Chemical compound OC(=O)C[C@@H](N)C[C@H](C)CCC1CCCC1 HDLUMIBBUPOCSA-PWSUYJOCSA-N 0.000 claims description 3
- YEJJKVAYXOGIIA-UHFFFAOYSA-N 2,3-dihydro-1h-isoindole-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1CNC2 YEJJKVAYXOGIIA-UHFFFAOYSA-N 0.000 claims description 3
- KYZTUNCFUQURFU-UHFFFAOYSA-N 2-(1-aminoethyl)benzoic acid Chemical compound CC(N)C1=CC=CC=C1C(O)=O KYZTUNCFUQURFU-UHFFFAOYSA-N 0.000 claims description 3
- WMDGTVJCXLXQME-UHFFFAOYSA-N 2-(2-isoquinolin-7-ylsulfanylethylamino)acetic acid Chemical compound C1=CN=CC2=CC(SCCNCC(=O)O)=CC=C21 WMDGTVJCXLXQME-UHFFFAOYSA-N 0.000 claims description 3
- HCQGVISMHVQRMT-UHFFFAOYSA-N 2-(3-amino-5-methyl-3-bicyclo[3.2.0]heptanyl)acetic acid Chemical compound C1C(N)(CC(O)=O)CC2(C)C1CC2 HCQGVISMHVQRMT-UHFFFAOYSA-N 0.000 claims description 3
- UZBRCPNWYDNMNB-UHFFFAOYSA-N 2-(4-phenylbutylamino)acetic acid;hydrochloride Chemical compound Cl.OC(=O)CNCCCCC1=CC=CC=C1 UZBRCPNWYDNMNB-UHFFFAOYSA-N 0.000 claims description 3
- KFUYJCLUBOFHHM-UHFFFAOYSA-N 2-(aminomethyl)-3-(1-methylcyclopropyl)propanoic acid Chemical compound NCC(C(O)=O)CC1(C)CC1 KFUYJCLUBOFHHM-UHFFFAOYSA-N 0.000 claims description 3
- POJKDIZXVVJRGB-UHFFFAOYSA-N 2-(aminomethyl)-3-bromobenzoic acid Chemical compound NCC1=C(Br)C=CC=C1C(O)=O POJKDIZXVVJRGB-UHFFFAOYSA-N 0.000 claims description 3
- VCOJPHSIBVJVDU-UHFFFAOYSA-N 2-(aminomethyl)-4,4,8-trimethylnonanoic acid Chemical compound CC(C)CCCC(C)(C)CC(CN)C(O)=O VCOJPHSIBVJVDU-UHFFFAOYSA-N 0.000 claims description 3
- PGWUHTMNEHONRF-UHFFFAOYSA-N 2-(aminomethyl)-4,5-dichlorobenzoic acid Chemical compound NCC1=CC(Cl)=C(Cl)C=C1C(O)=O PGWUHTMNEHONRF-UHFFFAOYSA-N 0.000 claims description 3
- QRNWJQJJPFXIDQ-UHFFFAOYSA-N 2-(aminomethyl)-4,6-dimethylheptanoic acid Chemical compound CC(C)CC(C)CC(CN)C(O)=O QRNWJQJJPFXIDQ-UHFFFAOYSA-N 0.000 claims description 3
- NETRIHFONCPRQM-UHFFFAOYSA-N 2-(aminomethyl)-4-cyclohexyl-3-methylbutanoic acid Chemical compound NCC(C(O)=O)C(C)CC1CCCCC1 NETRIHFONCPRQM-UHFFFAOYSA-N 0.000 claims description 3
- JVYGCKSEDCBNBD-UHFFFAOYSA-N 2-(aminomethyl)-4-ethyl-8-methylnonanoic acid Chemical compound NCC(C(O)=O)CC(CC)CCCC(C)C JVYGCKSEDCBNBD-UHFFFAOYSA-N 0.000 claims description 3
- IVYDEZGCXPEAHO-UHFFFAOYSA-N 2-(aminomethyl)-4-methylheptanoic acid Chemical compound CCCC(C)CC(CN)C(O)=O IVYDEZGCXPEAHO-UHFFFAOYSA-N 0.000 claims description 3
- ATYKFZPYPABAPV-UHFFFAOYSA-N 2-(aminomethyl)-5-chlorobenzoic acid Chemical compound NCC1=CC=C(Cl)C=C1C(O)=O ATYKFZPYPABAPV-UHFFFAOYSA-N 0.000 claims description 3
- WVFBDMDEDAUCIX-UHFFFAOYSA-N 2-(aminomethyl)-6-chlorobenzoic acid Chemical compound NCC1=CC=CC(Cl)=C1C(O)=O WVFBDMDEDAUCIX-UHFFFAOYSA-N 0.000 claims description 3
- JXSBZOVCVUSLIO-NQMVMOMDSA-N 2-[(1r,5r,6s)-6-(aminomethyl)-6-bicyclo[3.2.0]heptanyl]acetic acid Chemical compound C1CC[C@H]2[C@@](CN)(CC(O)=O)C[C@H]21 JXSBZOVCVUSLIO-NQMVMOMDSA-N 0.000 claims description 3
- IUVMAUQEZFTTFB-UHFFFAOYSA-N 2-[1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid Chemical compound CC1CC(CN)(CC(O)=O)CC1C IUVMAUQEZFTTFB-UHFFFAOYSA-N 0.000 claims description 3
- UOPIILYKLVDKTK-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclohexyl]acetic acid Chemical compound CC1CCCC(CN)(CC(O)=O)C1 UOPIILYKLVDKTK-UHFFFAOYSA-N 0.000 claims description 3
- HYVKVSAZCPKHDV-UHFFFAOYSA-N 2-[1-(aminomethyl)-3-methylcyclopentyl]acetic acid Chemical compound CC1CCC(CN)(CC(O)=O)C1 HYVKVSAZCPKHDV-UHFFFAOYSA-N 0.000 claims description 3
- JDKOOJRWDUPFIF-UHFFFAOYSA-N 2-[2-(3-chlorophenoxy)butylamino]acetic acid dihydrochloride Chemical compound Cl.Cl.ClC=1C=C(OC(CNCC(=O)O)CC)C=CC1 JDKOOJRWDUPFIF-UHFFFAOYSA-N 0.000 claims description 3
- NDKMRSPIBYXZSP-UHFFFAOYSA-N 2-[2-(4-chlorophenoxy)propylamino]acetic acid Chemical compound OC(=O)CNCC(C)OC1=CC=C(Cl)C=C1 NDKMRSPIBYXZSP-UHFFFAOYSA-N 0.000 claims description 3
- CBBXOQZPBGQURC-UHFFFAOYSA-N 2-[2-(4-chlorophenoxy)propylamino]acetic acid;hydrochloride Chemical compound Cl.OC(=O)CNCC(C)OC1=CC=C(Cl)C=C1 CBBXOQZPBGQURC-UHFFFAOYSA-N 0.000 claims description 3
- SXVXVAPJICBEFD-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)sulfanylethylamino]acetic acid Chemical compound OC(=O)CNCCSC1=CC=C(Cl)C=C1 SXVXVAPJICBEFD-UHFFFAOYSA-N 0.000 claims description 3
- CLTIAOXFZMTVFG-UHFFFAOYSA-N 2-[2-[4-(aminomethyl)phenyl]sulfanylethylamino]acetic acid Chemical compound NCC1=CC=C(SCCNCC(O)=O)C=C1 CLTIAOXFZMTVFG-UHFFFAOYSA-N 0.000 claims description 3
- UVUQVKDHNYUOJX-UHFFFAOYSA-N 2h-oxadiazol-5-one;hydrochloride Chemical compound Cl.O=C1C=NNO1 UVUQVKDHNYUOJX-UHFFFAOYSA-N 0.000 claims description 3
- SIRQBZJUYVPMIC-UHFFFAOYSA-N 3-(aminomethyl)-5-methylheptanoic acid Chemical compound CCC(C)CC(CN)CC(O)=O SIRQBZJUYVPMIC-UHFFFAOYSA-N 0.000 claims description 3
- AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 claims description 3
- PVOZHPMILBKJAX-UHFFFAOYSA-N 3-amino-5-methyl-7-phenylheptanoic acid Chemical compound OC(=O)CC(N)CC(C)CCC1=CC=CC=C1 PVOZHPMILBKJAX-UHFFFAOYSA-N 0.000 claims description 3
- XKWDZEJCUWTBOM-UHFFFAOYSA-N 3-amino-5-methylnonanoic acid Chemical compound CCCCC(C)CC(N)CC(O)=O XKWDZEJCUWTBOM-UHFFFAOYSA-N 0.000 claims description 3
- JXEHXYFSIOYTAH-UHFFFAOYSA-N 3-amino-5-methyloctanoic acid Chemical compound CCCC(C)CC(N)CC(O)=O JXEHXYFSIOYTAH-UHFFFAOYSA-N 0.000 claims description 3
- GSXLSVGQNPZFRS-UHFFFAOYSA-N 3-amino-7-(2,4-difluorophenyl)-5-methylheptanoic acid Chemical compound OC(=O)CC(N)CC(C)CCC1=CC=C(F)C=C1F GSXLSVGQNPZFRS-UHFFFAOYSA-N 0.000 claims description 3
- VNEAZJRSFULCJJ-UHFFFAOYSA-N 3-amino-7-cyclohexyl-5-methylheptanoic acid Chemical compound OC(=O)CC(N)CC(C)CCC1CCCCC1 VNEAZJRSFULCJJ-UHFFFAOYSA-N 0.000 claims description 3
- HDLUMIBBUPOCSA-UHFFFAOYSA-N 3-amino-7-cyclopentyl-5-methylheptanoic acid Chemical compound OC(=O)CC(N)CC(C)CCC1CCCC1 HDLUMIBBUPOCSA-UHFFFAOYSA-N 0.000 claims description 3
- FRXVVOBOAUAOCA-UHFFFAOYSA-N 3-amino-8-(2,3-difluorophenyl)-5-methyloctanoic acid Chemical compound OC(=O)CC(N)CC(C)CCCC1=CC=CC(F)=C1F FRXVVOBOAUAOCA-UHFFFAOYSA-N 0.000 claims description 3
- WXJZPMQTLWNDGI-UHFFFAOYSA-N 3-amino-8-(2,4-difluorophenyl)-5-methyloctanoic acid Chemical compound OC(=O)CC(N)CC(C)CCCC1=CC=C(F)C=C1F WXJZPMQTLWNDGI-UHFFFAOYSA-N 0.000 claims description 3
- IUVMAUQEZFTTFB-YUMQZZPRSA-N Atagabalin Chemical compound C[C@H]1CC(CN)(CC(O)=O)C[C@@H]1C IUVMAUQEZFTTFB-YUMQZZPRSA-N 0.000 claims description 3
- NDAOFSCNZJZRFK-UHFFFAOYSA-N Cl.CSC1=CC=C(SCCNCC(O)=O)C=C1 Chemical compound Cl.CSC1=CC=C(SCCNCC(O)=O)C=C1 NDAOFSCNZJZRFK-UHFFFAOYSA-N 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 3
- JXEHXYFSIOYTAH-SFYZADRCSA-N imagabalin Chemical compound CCC[C@@H](C)C[C@H](N)CC(O)=O JXEHXYFSIOYTAH-SFYZADRCSA-N 0.000 claims description 3
- 229960001233 pregabalin Drugs 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 32
- 230000000694 effects Effects 0.000 description 15
- 241000282412 Homo Species 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000000883 anti-obesity agent Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- ANJTVLIZGCUXLD-BDAKNGLRSA-N (-)-Cytisine Natural products C1NC[C@@H]2CN3C(=O)C=CC=C3[C@H]1C2 ANJTVLIZGCUXLD-BDAKNGLRSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- ANJTVLIZGCUXLD-DTWKUNHWSA-N cytisine Chemical compound C1NC[C@H]2CN3C(=O)C=CC=C3[C@@H]1C2 ANJTVLIZGCUXLD-DTWKUNHWSA-N 0.000 description 3
- 229940027564 cytisine Drugs 0.000 description 3
- 229930017327 cytisine Natural products 0.000 description 3
- ANJTVLIZGCUXLD-UHFFFAOYSA-N ent-cytisine Natural products C1NCC2CN3C(=O)C=CC=C3C1C2 ANJTVLIZGCUXLD-UHFFFAOYSA-N 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002904 solvent Chemical class 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003653 radioligand binding assay Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 102000005861 leptin receptors Human genes 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 210000001009 nucleus accumben Anatomy 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49735303P | 2003-08-22 | 2003-08-22 | |
| PCT/IB2004/002604 WO2005018622A1 (en) | 2003-08-22 | 2004-08-09 | A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007503384A true JP2007503384A (ja) | 2007-02-22 |
| JP2007503384A5 JP2007503384A5 (https=) | 2007-09-13 |
Family
ID=34216115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523699A Abandoned JP2007503384A (ja) | 2003-08-22 | 2004-08-09 | 肥満症の治療又は体重減量を容易にする若しくは促進するための医薬組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050043406A1 (https=) |
| EP (1) | EP1658059A1 (https=) |
| JP (1) | JP2007503384A (https=) |
| BR (1) | BRPI0413670A (https=) |
| CA (1) | CA2534271A1 (https=) |
| MX (1) | MXPA06002049A (https=) |
| WO (1) | WO2005018622A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005000806A2 (en) * | 2003-06-10 | 2005-01-06 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
| BRPI0414781A (pt) * | 2003-09-25 | 2006-11-21 | Warner Lambert Co | aminoácidos com afinidade para a proteìna (alfa)2(delta) |
| BRPI0414798A (pt) | 2003-09-25 | 2006-11-21 | Warner Lambert Co | métodos para usar aminoácidos com afinidade para a proteìna alfa2delta |
| WO2007115092A2 (en) * | 2006-03-29 | 2007-10-11 | Georgetown University | 10-substituted cytisine derivatives and methods of use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69839131T3 (de) * | 1997-12-31 | 2015-05-07 | Pfizer Products Inc. | Arylkondensierte azapolycyclische derivate |
| WO2000067742A2 (en) * | 1999-05-05 | 2000-11-16 | Warner-Lambert Company | Use of gaba analogues for the modulation of substance p |
| US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| US20020010192A1 (en) * | 2000-06-02 | 2002-01-24 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
-
2004
- 2004-06-17 US US10/870,208 patent/US20050043406A1/en not_active Abandoned
- 2004-08-09 BR BRPI0413670-5A patent/BRPI0413670A/pt not_active IP Right Cessation
- 2004-08-09 EP EP04744239A patent/EP1658059A1/en not_active Withdrawn
- 2004-08-09 WO PCT/IB2004/002604 patent/WO2005018622A1/en not_active Ceased
- 2004-08-09 JP JP2006523699A patent/JP2007503384A/ja not_active Abandoned
- 2004-08-09 MX MXPA06002049A patent/MXPA06002049A/es unknown
- 2004-08-09 CA CA002534271A patent/CA2534271A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1658059A1 (en) | 2006-05-24 |
| CA2534271A1 (en) | 2005-03-03 |
| MXPA06002049A (es) | 2006-05-19 |
| WO2005018622A1 (en) | 2005-03-03 |
| BRPI0413670A (pt) | 2006-10-24 |
| US20050043406A1 (en) | 2005-02-24 |
| WO2005018622A8 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11773051B2 (en) | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same | |
| EP2282779B1 (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | |
| TWI440456B (zh) | 用於治療代謝性症候群之新穎化合物 | |
| EP2282778A2 (en) | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of angiogenesis | |
| US20090012177A1 (en) | Treatment of psychiatric disorders using entacapone, tolcapone and other COMT inhibitor or MB-COMT inhibitor drugs | |
| WO2018075481A1 (en) | Compounds, compositions and methods for treating or preventing depression and other diseases | |
| US9861594B2 (en) | Treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder | |
| JP2007503384A (ja) | 肥満症の治療又は体重減量を容易にする若しくは促進するための医薬組成物 | |
| US20030176457A1 (en) | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | |
| Amiri | Recent advances in the treatment of renal diseases with nebivolol: A literature review | |
| US20050043407A1 (en) | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | |
| JP4588016B2 (ja) | 腎不全処置方法 | |
| US20090306050A1 (en) | Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain | |
| US20080261955A1 (en) | Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression | |
| HK40105809A (zh) | 美维达林和其他d1正向别构调节剂用於减缓帕金森氏病进展的用途 | |
| CA2912302A1 (en) | Compositions and methods for treating cardiometabolic diseases and disorders | |
| MXPA01005550A (en) | A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss, comprising a nicotine receptor partial agonist and an anti-obesity agent | |
| WO2019073045A1 (en) | USE OF DONORS OF NO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070719 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070719 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20080304 |